Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 11c; Offers Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $60.76 million versus the consensus estimate of $56.85 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2023 revenue of $375-385 million, versus the consensus of $382.7 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance
• Build-A-Bear Workshop (BBW) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY Guidance